A5001678596- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Retinoids in leukemia and cellular processes
- Biosimilars and Bioanalytical Methods
- Immunotherapy and Immune Responses
- Hematopoietic Stem Cell Transplantation
- Vascular Tumors and Angiosarcomas
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ubiquitin and proteasome pathways
- Brain Metastases and Treatment
- Gut microbiota and health
- Glioma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Histiocytic Disorders and Treatments
University Hospital Regensburg
2015-2025
University of Regensburg
2007-2025
Center for Cancer Research
2023
University of California, San Diego
2012
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating safety feasibility of chimeric receptor (CAR) T cells targeting CLDN6 with or without CAR-T cell-amplifying RNA vaccine (CARVac) at two levels (DLs) relapsed/refractory CLDN6-positive tumors. primary endpoints were tolerability, maximum tolerated recommended 2 (RP2D)....
321 Background: Second-line treatment options for patients with biliary tract cancers (BTC) are limited. Lenvatinib, an anti-angiogenic multikinase inhibitor, in combination the programmed death-1 immune checkpoint inhibitor pembrolizumab, has demonstrated promising antitumor activity a manageable safety profile select advanced solid tumors. LEAP-005 (NCT03797326) is evaluating efficacy and of lenvatinib plus pembrolizumab previously treated tumors; here we present results from BTC cohort...
Abstract The clinical course of coronavirus disease 2019 (COVID‐19) varies from mild symptoms to acute respiratory distress syndrome, hyperinflammation, and coagulation disorder. hematopoietic system plays a critical role in the observed particularly severely ill patients. We conducted prospective diagnostic study performing blood differential analyzing morphologic changes peripheral COVID‐19 associated were defined training cohort subsequently validated second (n = 45). Morphologic...
Introduction Tertiary prevention through physical activity and psychosocial support can positively impact patient outcomes, such as function quality of life (QoL). However, more research is required on the effectiveness strategies designed to increase uptake tertiary programmes among cancer patients. Here, we present protocol for a single-centre, randomised controlled pilot trial testing preliminary social prescription virtual information in increasing patients persons (SPs) (ESPRIT “ E...
Zusammenfassung Zerebrale Metastasen bei Patienten mit Lungenkarzinom im Stadium der Metastasierung finden sich bereits mehr als 30% zum Zeitpunkt Erstdiagnose und manifestieren Verlauf Erkrankung 2 von 3 Patienten. Die zerebrale Krankheitsmanifestation wurde lange Zeit prognostisch ungünstig eingestuft. Betroffene wurden regelhaft Therapiestudien unter Berücksichtigung ungünstigen Prognose ausgeschlossen. Im Kontext zielgerichteter molekularer Therapiestrategien etablierter...
Multiple Myeloma (MM) is an incurable plasma cell malignancy primarily localized within the bone marrow (BM). It develops from a premalignant stage, monoclonal gammopathy of undetermined significance (MGUS), often via intermediate smoldering MM (SMM). The mechanisms progression have not yet been fully understood, all more because patients with MGUS and SMM already carry similar initial mutations as found in cells. Over last years, increased importance has attributed to tumor microenvironment...
Metabolic pathways regulate immune responses and disrupted metabolism leads to dysfunction disease. Coronavirus disease 2019 (COVID-19) is driven by imbalanced responses, yet the role of immunometabolism in COVID-19 pathogenesis remains unclear. By investigating 87 patients with confirmed SARS-CoV-2 infection, 6 critically ill non–COVID-19 patients, 47 uninfected controls, we found an immunometabolic dysregulation progressed COVID-19. Specifically, T cells, monocytes, granulocytes exhibited...
4080 Background: Second-line treatment options for patients with biliary tract cancers (BTC) are limited. Lenvatinib, an anti-angiogenic multikinase inhibitor, in combination the programmed death-1 immune checkpoint inhibitor pembrolizumab, has demonstrated promising antitumor activity a manageable safety profile select advanced solid tumors. LEAP-005 (NCT03797326) is evaluating efficacy and of lenvatinib plus pembrolizumab previously treated tumors; here we present results from BTC cohort...
Abstract Background: BNT211 comprises two drug products, a chimeric antigen receptor (CAR)-T cell product candidate that targets the tumor specific claudin 6 (CLDN6) and CAR-T cell-Amplifying RNA Vaccine (CARVac). In mice, CARVac mediates expansion of adoptively transferred cells, improving their persistence functionality. aims to establish therapy for CLDN6-positive solid tumors. Methods: This first-in-human, open label, multi-center trial involves bifurcated 3+3 design with CLDN6 dose...
Abstract Background Recently, molecular tumour boards (MTBs) have been integrated into the clinical routine. Since their benefit remains debated, we assessed MTB outcomes in Comprehensive Cancer Center Ostbayern (CCCO) from 2019 to 2021. Methods and results In total, 251 patients were included. Targeted sequencing was performed with PCR MSI-evaluation immunohistochemistry for PD-L1, Her2, mismatch repair enzymes. 125 treatment recommendations given (49.8%). High-recommendation rates achieved...
Targeted chemotherapy and immune checkpoint inhibitors (ICPi) have expanded the spectrum of therapies for patients with relapsed/refractory (r/r) Hodgkin’s disease significantly improved proportion long-term control. However, there is no standardized therapeutic option in case further progression. Recently, we demonstrated that therapy MEPED (metronomic chemotherapy, everolimus, pioglitazone, etoricoxib, dexamethasone) highly effective r/r disease. The benefit after pre-treatment ICPi has...
(1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the regional impact outreach component of MTBs; (2) Methods: we analyzed MTB patient data from four neighboring Bavarian tertiary care oncology centers in Würzburg, Erlangen, Regensburg, Augsburg, together constituting WERA Alliance. Absolute numbers distribution across...
2518 Background: We are developing a chimeric antigen receptor (CAR)-T cell therapy targeting claudin 6 (CLDN6), an oncofetal that is undetectable in healthy somatic tissue and highly expressed various solid cancers. Autologous CLDN6 CAR-T cells being tested alone combination with CLDN6-encoding Amplifying RNA Vaccine (CARVac), nanoparticulate vaccine designed to stimulate expand cells. Methods: The ongoing first-in-human trial BNT211-01 evaluates the safety feasibility of transfer ± CARVac...